Arketamine for bipolar depression: Open-label, dose-escalation, pilot study.

Publication date: Aug 01, 2023

There are significantly fewer options for the treatment of bipolar depression than major depressive disorder, with an urgent need for alternative therapies. In this pilot study, we treated six subjects with bipolar disorder types I and II (according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria) who had been in a current depressive episode for at least four weeks. Four subjects were female (66. 66%), and the mean age was 45. 33 (+/-12. 32). Subjects received adjunct treatment with two arketamine intravenous infusions one week apart-0. 5 mg/kg first and then 1 mg/kg. The mean baseline Montgomery-Asberg Depression Rating Scale (MADRS) total score was 36. 66, which decreased to 27. 83 24h after the first infusion of 0. 5 mg/kg of arketamine (p = 0. 036). In respect of the 1 mg/kg dose, the mean MADRS total score before the second infusion was 32. 0, which dropped to 17. 66 after 24h (p

Concepts Keywords
5mg Antidepressant
Depressive Arketamine
Intravenous Bipolar depression
Pilot Bipolar disorder
Week Glutamate
Major depression


Type Source Name
disease MESH bipolar depression
disease MESH major depressive disorder
disease MESH Mental Disorders
drug DRUGBANK Ketamine

Original Article

(Visited 1 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *